Paper
Journal of Commercial Biotechnology (2003) 9, 209–218; doi:10.1057/palgrave.jcb.3040030
Spinning off, cashing up and branching out: Commercialisation considerations for bioentrepreneurs in Australasia
Nick Wells1, Brendan Coady2 and Josephine Inge3
- 1Chapman Tripp, New Zealand, Tel: +649 357 9004, Fax: +649 357 9099, Email: nick.wells@chapmantripp.com
- 2Gilbert + Tobin, Australia, Tel: +612 9263 4065, Fax: +612 9263 4111, Email: bcoady@gtlaw.com.au
- 3Gilbert + Tobin's Intellectual Property Group
Revised 13 February 2003.
Top of page
Abstract
There are myriad issues to consider when commercialising a biotechnological innovation. In Australia, because of market structure, the tendency for biotechnology companies to list early in their life cycles has caused problems. A fledgling venture capital market in Australia has been partly to blame. The authors outline practical, strategic considerations for bioentrepreneurs in Australasia, focusing on innovations stemming from biomedical research.
Keywords:
life science, biotechnology, spin-out companies, venture capital, fund raising, IPO, tax reform, second board
